By drugdelivery
Taris Biomedical hit the ground running, raising $15 million from venture fund backers for its launch.
The Lexington-based drug-device developer, which is aiming to leverage lidocaine delivery technology developed at MIT to treat bladder conditions, said (PDF) Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners led the investment round.
By drugdelivery
MassDevice caught Rob Campbell, Insulet Corp.‘s vice president of clinical research, on his way to dinner in Paris after a day spent lining up a distribution deal for the company’s flagship OmniPod insulin management system.
European Union regulators gave the nod for the device to hit the market there, meaning the Bedford-based diabetes device maker is cleared to start selling the OmniPod in countries that recognize the EU’s CE Mark.
By drugdelivery
Insulet Corp. took home the Best New Product award in the medical and science category at the 2009 Edison Awards for its OmniPod insulin pump.
The Google-sponsored awards are given to products that “excel in marketplace, innovation, marketplace success, technological innovation, market structure, innovation, and societal impact.” Past winners include Apple Computer, Johnson & Johnson and Chrysler.
By drugdelivery
Mass High Tech is reporting that Pulmatrix Inc., a Lexington-based biotechnology startup that’s developing inhaled therapies for respiratory infectious diseases, raised $3.5 million.
The company, which isn’t speaking publicly about the financing and only recently came out of stealth mode, is another Robert Langer company financed by Polaris Ventures of Waltham.
